ESR1 and triple-negative breast carcinoma: The re-expression of ER-α in triple-negative breast cancer cells following treatment with CAPE might indicate that CAPE could make triple-negative breast cancer patients susceptible to chemoprevention and anti-estrogen therapy if used in combination with hormone-based therapy, in either the adjuvant or metastatic setting.